Nature Communications (Apr 2024)

Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer

  • Meirion Raymant,
  • Yuliana Astuti,
  • Laura Alvaro-Espinosa,
  • Daniel Green,
  • Valeria Quaranta,
  • Gaia Bellomo,
  • Mark Glenn,
  • Vatshala Chandran-Gorner,
  • Daniel H. Palmer,
  • Christopher Halloran,
  • Paula Ghaneh,
  • Neil C. Henderson,
  • Jennifer P. Morton,
  • Manuel Valiente,
  • Ainhoa Mielgo,
  • Michael C. Schmid

DOI
https://doi.org/10.1038/s41467-024-47949-3
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 22

Abstract

Read online

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease for which better therapies are urgently needed. Fibroblasts and macrophages are heterogeneous cell populations able to enhance metastasis, but the role of a macrophage-fibroblast crosstalk in regulating their pro-metastatic functions remains poorly understood. Here we deconvolve how macrophages regulate metastasis-associated fibroblast (MAF) heterogeneity in the liver. We identify three functionally distinct MAF populations, among which the generation of pro-metastatic and immunoregulatory myofibroblastic-MAFs (myMAFs) critically depends on macrophages. Mechanistically, myMAFs are induced through a STAT3-dependent mechanism driven by macrophage-derived progranulin and cancer cell-secreted leukaemia inhibitory factor (LIF). In a reciprocal manner, myMAF secreted osteopontin promotes an immunosuppressive macrophage phenotype resulting in the inhibition of cytotoxic T cell functions. Pharmacological blockade of STAT3 or myMAF-specific genetic depletion of STAT3 restores an anti-tumour immune response and reduces metastases. Our findings provide molecular insights into the complex macrophage–fibroblast interactions in tumours and reveal potential targets to inhibit PDAC liver metastasis.